168 related articles for article (PubMed ID: 35307743)
1. Intratumoral heterogeneity of MYC drives medulloblastoma metastasis and angiogenesis.
Qin N; Paisana E; Langini M; Picard D; Malzkorn B; Custódia C; Cascão R; Meyer FD; Blümel L; Göbbels S; Taban K; Bartl J; Bechmann N; Conrad C; Gravemeyer J; Becker JC; Stefanski A; Puget S; Barata JT; Stühler K; Fischer U; Felsberg J; Ayrault O; Reifenberger G; Borkhardt A; Eisenhofer G; Faria CC; Remke M
Neuro Oncol; 2022 Sep; 24(9):1509-1523. PubMed ID: 35307743
[TBL] [Abstract][Full Text] [Related]
2. Somatic cell transfer of c-Myc and Bcl-2 induces large-cell anaplastic medulloblastomas in mice.
Jenkins NC; Rao G; Eberhart CG; Pedone CA; Dubuc AM; Fults DW
J Neurooncol; 2016 Feb; 126(3):415-24. PubMed ID: 26518543
[TBL] [Abstract][Full Text] [Related]
3.
Tao R; Murad N; Xu Z; Zhang P; Okonechnikov K; Kool M; Rivero-Hinojosa S; Lazarski C; Zheng P; Liu Y; Eberhart CG; Rood BR; Packer R; Pei Y
Cancer Res; 2019 Apr; 79(8):1967-1980. PubMed ID: 30862721
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.
Venkataraman S; Alimova I; Balakrishnan I; Harris P; Birks DK; Griesinger A; Amani V; Cristiano B; Remke M; Taylor MD; Handler M; Foreman NK; Vibhakar R
Oncotarget; 2014 May; 5(9):2355-71. PubMed ID: 24796395
[TBL] [Abstract][Full Text] [Related]
5. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.
Ellison DW; Kocak M; Dalton J; Megahed H; Lusher ME; Ryan SL; Zhao W; Nicholson SL; Taylor RE; Bailey S; Clifford SC
J Clin Oncol; 2011 Apr; 29(11):1400-7. PubMed ID: 20921458
[TBL] [Abstract][Full Text] [Related]
6. "Large cell/anaplastic" medulloblastomas: a Pediatric Oncology Group Study.
Brown HG; Kepner JL; Perlman EJ; Friedman HS; Strother DR; Duffner PK; Kun LE; Goldthwaite PT; Burger PC
J Neuropathol Exp Neurol; 2000 Oct; 59(10):857-65. PubMed ID: 11079775
[TBL] [Abstract][Full Text] [Related]
7. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma.
Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW
Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591
[TBL] [Abstract][Full Text] [Related]
8. Low-level copy gain versus amplification of myc oncogenes in medulloblastoma: utility in predicting prognosis and survival. Laboratory investigation.
Takei H; Nguyen Y; Mehta V; Chintagumpala M; Dauser RC; Adesina AM
J Neurosurg Pediatr; 2009 Jan; 3(1):61-5. PubMed ID: 19119907
[TBL] [Abstract][Full Text] [Related]
9. Frondoside A Inhibits an MYC-Driven Medulloblastoma Model Derived from Human-Induced Pluripotent Stem Cells.
Xue Y; Fu Y; Zhao F; Gui G; Li Y; Rivero-Hinojosa S; Liu G; Li Y; Xia S; Eberhart CG; Ying M
Mol Cancer Ther; 2021 Jun; 20(6):1199-1209. PubMed ID: 33722850
[TBL] [Abstract][Full Text] [Related]
10. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia.
Eberhart CG; Kratz J; Wang Y; Summers K; Stearns D; Cohen K; Dang CV; Burger PC
J Neuropathol Exp Neurol; 2004 May; 63(5):441-9. PubMed ID: 15198123
[TBL] [Abstract][Full Text] [Related]
11. Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma.
Borgenvik A; Holmberg KO; Bolin S; Zhao M; Savov V; Rosén G; Hutter S; Garancher A; Rahmanto AS; Bergström T; Olsen TK; Mainwaring OJ; Sattanino D; Verbaan AD; Rusert JM; Sundström A; Bravo MB; Dang Y; Wenz AS; Richardson S; Fotaki G; Hill RM; Dubuc AM; Kalushkova A; Remke M; Čančer M; Jernberg-Wiklund H; Giraud G; Chen X; Taylor MD; Sangfelt O; Clifford SC; Schüller U; Wechsler-Reya RJ; Weishaupt H; Swartling FJ
Cancer Res; 2022 Dec; 82(24):4586-4603. PubMed ID: 36219398
[TBL] [Abstract][Full Text] [Related]
12. NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma.
Fiaschetti G; Schroeder C; Castelletti D; Arcaro A; Westermann F; Baumgartner M; Shalaby T; Grotzer MA
Acta Neuropathol Commun; 2014 Apr; 2():39. PubMed ID: 24708907
[TBL] [Abstract][Full Text] [Related]
13. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.
Korshunov A; Remke M; Werft W; Benner A; Ryzhova M; Witt H; Sturm D; Wittmann A; Schöttler A; Felsberg J; Reifenberger G; Rutkowski S; Scheurlen W; Kulozik AE; von Deimling A; Lichter P; Pfister SM
J Clin Oncol; 2010 Jun; 28(18):3054-60. PubMed ID: 20479417
[TBL] [Abstract][Full Text] [Related]
14. Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features.
Leonard JR; Cai DX; Rivet DJ; Kaufman BA; Park TS; Levy BK; Perry A
J Neurosurg; 2001 Jul; 95(1):82-8. PubMed ID: 11453402
[TBL] [Abstract][Full Text] [Related]
15. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors.
Northcott PA; Fernandez-L A; Hagan JP; Ellison DW; Grajkowska W; Gillespie Y; Grundy R; Van Meter T; Rutka JT; Croce CM; Kenney AM; Taylor MD
Cancer Res; 2009 Apr; 69(8):3249-55. PubMed ID: 19351822
[TBL] [Abstract][Full Text] [Related]
16. Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma.
Zhou L; Picard D; Ra YS; Li M; Northcott PA; Hu Y; Stearns D; Hawkins C; Taylor MD; Rutka J; Der SD; Huang A
Cancer Res; 2010 Oct; 70(20):8199-210. PubMed ID: 20876797
[TBL] [Abstract][Full Text] [Related]
17. Metabolism-based targeting of MYC via MPC-SOD2 axis-mediated oxidation promotes cellular differentiation in group 3 medulloblastoma.
Martell E; Kuzmychova H; Kaul E; Senthil H; Chowdhury SR; Morrison LC; Fresnoza A; Zagozewski J; Venugopal C; Anderson CM; Singh SK; Banerji V; Werbowetski-Ogilvie TE; Sharif T
Nat Commun; 2023 May; 14(1):2502. PubMed ID: 37130865
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional control of DNA repair networks by CDK7 regulates sensitivity to radiation in MYC-driven medulloblastoma.
Veo B; Danis E; Pierce A; Wang D; Fosmire S; Sullivan KD; Joshi M; Khanal S; Dahl N; Karam S; Serkova N; Venkataraman S; Vibhakar R
Cell Rep; 2021 Apr; 35(4):109013. PubMed ID: 33910002
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma.
Vo BT; Li C; Morgan MA; Theurillat I; Finkelstein D; Wright S; Hyle J; Smith SMC; Fan Y; Wang YD; Wu G; Orr BA; Northcott PA; Shilatifard A; Sherr CJ; Roussel MF
Cell Rep; 2017 Mar; 18(12):2907-2917. PubMed ID: 28329683
[TBL] [Abstract][Full Text] [Related]
20. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
